Lilly Zyprexa Rebound Plan Begins With Approval For Bipolar Maintenance
Executive Summary
Lilly hopes that approval of Zyprexa for use as bipolar maintenance therapy will help fuel a rebound in prescriptions for the atypical antipsychotic, CEO Sidney Taurel said Jan. 13 at the J.P. Morgan health care conference in San Francisco
You may also be interested in...
Lilly Symbyax Combo Clears FDA; Price, Dose Will Help Distinguish Brand
Lilly's launch plans for the bipolar depression therapy Symbyax combine a value pricing model with a unique dosing combination
Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates
Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class